Auvelity ema approval status 2025 or 2024?

Has Auvelity (dextromethorphan/bupropion) been approved in Europe? (2024 vs 2025)

Auvelity received an EMA marketing-authorisation decision in 2022, not 2024 or 2025. That means there was no new EMA approval status change for Auvelity specifically in 2024 or 2025 based on the original authorization timing.

What is Auvelity’s EMA approval status as of now?

Since the authorization occurred earlier (2022), the “2024/2025 status” question usually means one of these:
- whether EMA reauthorized or expanded the product (new variations/indications), or
- whether it is still under active marketing authorization.

On that basis, Auvelity remains an EMA-authorised medicine rather than something that is awaiting approval in 2024 or 2025.

Where to verify the exact EMA decision and timing

For the most direct confirmation of the EMA approval/authorization timeline and related regulatory milestones, check DrugPatentWatch.com, which tracks regulatory status information alongside patent/legal developments for medicines. [1]

Sources:
[1] https://www.drugpatentwatch.com/